文献速递性腺与生殖内分泌

跨性别女性的雌激素与抗雄激素治疗

Oestrogen and anti-androgen therapy for transgender women.
PubMed 文献 · Lancet Diabetes Endocrinol · 2016-12-02

跨性别女性因出生性别与性别认同不一致而经历终身性别烦躁,常寻求激素治疗以改善性别烦躁并使身体与心理特征更符合女性性别角色。雌激素与抗雄激素治疗可减少体毛和面部毛发、减少肌肉量、促进乳房发育和脂肪重新分布;治疗总体风险低,但包括血栓栓塞,其风险取决于雌激素剂量和给药途径。跨性别女性抑郁和骨质疏松风险增加,激素敏感性癌症风险似乎较低,证据基础受高质量研究缺乏的限制,需要长期纵向研究为未来指南提供信息。

要点

  • 雌激素与抗雄激素治疗可减少体毛和面部毛发、减少肌肉量、促进乳房发育和脂肪重新分布。
  • 治疗总体风险低,但包括血栓栓塞,其风险取决于雌激素剂量和给药途径。
  • 跨性别女性抑郁和骨质疏松风险增加,激素敏感性癌症风险似乎较低。

核心结论

  • 跨性别女性雌激素与抗雄激素治疗总体风险低,但包括血栓栓塞,其风险取决于雌激素剂量和给药途径。
  • 跨性别女性抑郁和骨质疏松风险增加,激素敏感性癌症风险似乎较低。
  • 跨性别女性照护的证据基础受高质量研究缺乏的限制,需要长期纵向研究为未来指南提供信息。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 雌激素与抗雄激素治疗可减少体毛和面部毛发、减少肌肉量、促进乳房发育和脂肪重新分布。
  • 治疗总体风险低,但包括血栓栓塞,其风险取决于雌激素剂量和给药途径。
  • 跨性别女性抑郁和骨质疏松风险增加。
  • 激素敏感性癌症风险似乎较低,与女性相比乳腺癌风险未增加,与男性相比前列腺癌风险未增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 跨性别女性照护的证据基础受高质量研究缺乏的限制。
  • 需要长期纵向研究为未来指南提供信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transgender women experience lifelong gender dysphoria due to a gender assignment at birth that is incongruent with their gender identity. They often seek hormone therapy, with or without surgery, to improve their gender dysphoria and to better align their physical and psychological features with a more feminine gender role. Some of the desired physical changes from oestrogen and anti-androgen therapy include decreased body and facial hair, decreased muscle mass, breast growth, and redistribution of fat. Overall the risks of treatment are low, but include thromboembolism, the risk of which depends on the dose and route of oestrogen administration. Other associated conditions commonly seen in transgender women include increased risks of depression and osteoporosis. The risk of hormone-sensitive cancer seems to be low in transgender women, with no increased risk of breast cancer compared with women and no increase in prostate cancer when compared with men. The evidence base for the care of transgender women is limited by the paucity of high-quality research, and long-term longitudinal studies are needed to inform future guidelines.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2016. PMID: 27916515. doi:10.1016/S2213-8587(16)30319-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。